Small molecule · developed by PTC Therapeutics
EPI-589 is an oral immediate-release film-coated tablet at a 250 mg strength, also known as (R)-troloxamide quinone.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT02460679 | Phase 2 | Amyotrophic Lateral Sclerosis | Completed | PTCT |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Amyotrophic Lateral Sclerosis
Updated Oct 25, 2026. Something wrong or missing? Report it on the PTCT page.
See PTCT's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
PTCT catalysts and pipeline →